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Abstract As part of its single technology appraisal pro-
cess, the National Institute for Health and Care Excellence
invited the manufacturer (Eli Lilly) of baricitinib (BARI;
Olumiant; a Janus kinase inhibitor that is taken orally) to
submit evidence of its clinical and cost effectiveness for the
treatment of moderate to severe rheumatoid arthritis (RA)
after the failure of disease-modifying antirheumatic drugs
(DMARDs). The School of Health and Related Research
Technology Appraisal Group at the University of Sheffield
was commissioned to act as the independent Evidence
Review Group (ERG). The ERG produced a detailed
review of the evidence for the clinical and cost effective-
ness of the technology, based on the company’s submission
(CS) to NICE. The clinical-effectiveness evidence in the
CS for BARI was based predominantly on three ran-
domised controlled trials comparing the efficacy of BARI
against adalimumab or placebo, as well as one long-term
extension study. The clinical-effectiveness review identi-
fied no head-to-head evidence on the efficacy of BARI
against all the comparators within the scope. Therefore, the
company performed network meta-analyses (NMAs) in
two different populations: one in patients who had expe-
rienced an inadequate response to conventional DMARDs
(cDMARD-IR), and the other in patients who had
experienced an inadequate response to tumour necrosis
factor inhibitors (TNFi-IR). The company’s NMAs con-
cluded BARI had comparable efficacy as the majority of its
comparators in both populations. The company submitted a
de novo discrete event simulation model that analysed the
incremental cost-effectiveness of BARI versus its com-
parators for the treatment of RA from the perspective of the
National Health Service (NHS) in four different popula-
tions: (1) cDMARD-IR patients with moderate RA, defined
as a 28-Joint Disease Activity Score (DAS28)[3.2 and no
more than 5.1; (2) cDMARD-IR patients with severe RA
(defined as a DAS28[5.1); (3) TNFi-IR patients with
severe RA for whom rituximab (RTX) was eligible; and (4)
TNFi-IR patients with severe RA for whom RTX in
combination with methotrexate (MTX) is contraindicated
or not tolerated. In the cDMARD-IR population with
moderate RA, the deterministic incremental cost-effec-
tiveness ratio (ICER) for BARI in combination with MTX
compared with intensive cDMARDs was estimated to be
£37,420 per quality-adjusted life-year (QALY) gained. In
the cDMARD-IR population with severe RA, BARI in
combination with MTX dominated all comparators except
for certolizumab pegol (CTZ) in combination with MTX,
with the ICER of CTZ in combination with MTX com-
pared with BARI in combination with MTX estimated to
be £18,400 per QALY gained. In the TNFi-IR population
with severe RA, when RTX in combination with MTX was
an option, BARI in combination with MTX was dominated
by RTX in combination with MTX. In the TNFi-IR pop-
ulation with severe RA for whom RTX in combination
with MTX is contraindicated or not tolerated, BARI in
combination with MTX dominated golimumab in combi-
nation with MTX and was less effective and less expensive
than the remaining comparators. Following a critique of the
model, the ERG undertook exploratory analyses after
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applying corrections to the methods used in the NMAs and
two programming errors in the economic model that
affected the company’s probabilistic sensitivity analysis
(PSA) results. The ERG’s NMA results were broadly
comparable with the company’s results. The programming
error that affected the PSA of the severe cDMARD-IR
population had only a minimal impact on the results, while
the error affecting the severe TNFi-IR RTX-ineligible
population resulted in markedly higher costs and QALYs
gained for the affected comparators but did not substan-
tially modify the conclusions of the analysis. The NICE
Appraisal Committee concluded that BARI in combination
with MTX or as monotherapy is a cost-effective use of
NHS resources in patients with severe RA, except in TNFi-
IR patients who are RTX-eligible.
Key Points for Decision Makers
Baricitinib (BARI) has shown comparable clinical
efficacy to the majority of recommended biologic
disease-modifying antirheumatic drugs (bDMARDs)
in previously treated moderate to severe rheumatoid
arthritis (RA).
A confidential Patient Access Scheme has been
agreed with the Department of Health under which
BARI will be available to the National Health
Service (NHS) at a reduced cost.
Estimated incremental cost-effectiveness ratios for
BARI, in combination with methotrexate (MTX) or
as monotherapy, versus its comparators, are within
the range usually considered as a cost-effective use
of NHS resources in patients with severe RA. The
exception is for patients who have had an inadequate
response to a tumour necrosis factor inhibitor (TNFi)
and who are eligible for rituximab (RTX) in
combination with MTX as RTX is of similar clinical
efficacy to BARI but has a significantly lower cost.
In patients with moderate RA and a 28-Joint Disease
Activity Score (DAS28) between 4.0 and 5.1, the
estimated ICER for BARI in combination with MTX
versus intensive conventional DMARDs was
estimated to be £37,420 per quality-adjusted life-
year gained.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) is an independent organisation responsible for
providing national guidance on promoting good health and
preventing and treating ill health in priority areas with
significant impact. Health technologies must be shown to
be clinically effective and to represent a cost-effective use
of National Health Service (NHS) resources in order for
NICE to recommend their use within the NHS in England.
The NICE single technology appraisal (STA) process
usually covers new single health technologies within a
single indication, soon after their UK market authorisation
[1]. Within the STA process, the company provides NICE
with a written submission, alongside a mathematical model
that summarises the company’s estimates of the clinical
and cost effectiveness of the technology. This submission
is reviewed by an external organisation independent of
NICE [the Evidence Review Group (ERG)], which con-
sults with clinical specialists and produces a report. After
consideration of the company’s submission (CS), the ERG
report and testimony from experts and other stakeholders,
the NICE Appraisal Committee (AC) formulates prelimi-
nary guidance, the Appraisal Consultation Document
(ACD), which indicates the initial decision of the AC
regarding the recommendation (or not) of the technology.
Stakeholders are then invited to comment on the submitted
evidence and the ACD, after which a further ACD may be
produced or a Final Appraisal Determination (FAD) issued,
which is open to appeal. An ACD is not typically produced
when the technology is recommended within its full mar-
keting authorisation; in this case, an FAD is produced
directly. In this STA, while there was a restriction on the
use of baricitinib (BARI), NICE directly produced an FAD
having considered the probability of an appeal.
This paper presents a summary of the ERG report [2] for
the STA of BARI for previously treated moderate to severe
rheumatoid arthritis (RA), and a summary of the subse-
quent development of the NICE guidance for the use of this
technology in England. Full details of all relevant appraisal
documents (including the appraisal scope, ERG report,
company and consultee submissions, FAD and comments
from consultees) can be found on the NICE website [3].
2 The Decision Problem
RA is an autoimmune disease that causes chronic inflam-
mation, progressive, irreversible joint damage, impaired
joint function, and pain and tenderness caused by swelling
of the synovial lining of joints. The condition is associated
with increasing disability and reduced health-related
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quality of life [4]. The primary symptoms are pain,
morning stiffness, swelling, tenderness, loss of movement,
fatigue, and redness of the peripheral joints [5, 6]. RA is
associated with substantial costs, both directly (due to
treatment acquisition and hospitalisation) and indirectly
(due to reduced productivity) [7]. The condition has long
been reported as being associated with increased mortality
[8, 9], particularly due to cardiovascular events [10]. NICE
estimates that there are 400,000 people in the UK with RA
[11], with approximately 26,000 incident cases per year
[12]. RA is more prevalent in females (3.6 per 100,000 per
year) than in males (1.5 per 100,000 per year) [13]. For
both sexes, the peak age of incidence in the UK is in the
eighth decade of life, but all ages can develop the disease
[13].
Two classifications have dominated the measurement of
improvement in RA symptoms: American College of
Rheumatology (ACR) responses [14] and European League
Against Rheumatism (EULAR) responses [15]. In the UK,
progression of RA is often monitored using the 28-Joint
Disease Activity Score (DAS28). The EULAR response
criteria use both the change in DAS28 and the absolute
DAS28 score to classify a response as good, moderate or
none [15]. Although EULAR response has been reported
less frequently in RCTs than ACR responses [16], it is
much more closely aligned to the treatment continuation
rules stipulated by NICE, which require at least a moderate
EULAR response or a DAS28 improvement of more than
1.2 points to continue treatment with biologic disease-
modifying antirheumatic drugs (bDMARDs).
2.1 Current Treatment
NICE recommends a combination of conventional
DMARDs (cDMARDs) as first-line treatment for people
with newly diagnosed RA, including methotrexate (MTX)
and at least one other cDMARD plus short-term gluco-
corticoids, ideally beginning within 3 months of the onset
of persistent symptoms [11].
For patients who have severe active RA (defined as a
DAS28[5.1), the NICE guidance recommends the use of
the following bDMARDs: abatacept (ABT), adalimumab
(ADA), certolizumab pegol (CTZ), etanercept (ETN),
golimumab (GOL), infliximab (IFX), or tocilizumab
(TCZ), each in combination with MTX after failure to
respond to cDMARDs [17, 18]. For patients with severe
RA for whom MTX is contraindicated or has been with-
drawn, the guidance recommends the use of ADA, CTZ,
ETN, or TCZ as monotherapy [17, 18]. Most of these drugs
(all except ABT and TCZ) are tumour necrosis factor
inhibitors (TNFis). After failure of the first TNFi, the
guidance recommends rituximab (RTX) in combination
with MTX for the treatment of severe active RA [19];
however, if RTX is contraindicated or withdrawn because
of an adverse event (AE), the guidance recommends ABT,
ADA, ETN, GOL, IFX, TCZ and CTZ in combination with
MTX [18–22]. Additionally, if MTX is contraindicated or
withdrawn because of an AE, the guidance recommends
ADA, ETN or CTZ [18, 19] as monotherapy. The guidance
also recommends TCZ in combination with MTX as a
third-line biologic after inadequate response to RTX in
combination with MTX [20], and recommends discontin-
uing treatment with bDMARDs unless a moderate EULAR
response is achieved at 6 months or if the response is not
maintained [18–22]. After treatment discontinuation, the
next treatment in the sequence is initiated.
3 The Independent Evidence Review Group
(ERG) Review
In accordance with the process for STAs, the ERG and
NICE had the opportunity to seek clarification on specific
points in the CS [23], in response to which the company
provided additional information [23]. Given the possibility
that BARI could be of similar efficacy and price to many of
the comparators, the ERG had agreed in advance with
NICE that if that were the case then the analyses under-
taken would not be extensive. As such, the STA was an
informal pilot for NICE’s fast-track appraisal that was
being introduced [24]. The ERG critiqued the network
meta-analyses (NMAs) undertaken by the company and
provided results from alternative NMAs. Errors identified
in the coding of the probabilistic sensitivity analyses (PSA)
performed by the company were corrected by the ERG.
The evidence presented in the CS, as well as the ERG’s
review of that evidence, is summarised here.
3.1 Clinical Evidence Provided by the Company
Evidence was presented in the CS [23] for the efficacy of
BARI in combination with MTX or as monotherapy in
previously treated moderate to severe RA. The key clini-
cal-effectiveness evidence was based on three randomised
controlled trials (RCTs). Two RCTs recruited MTX or
cDMARD intolerant or inadequate response (cDMARD-
IR) patients with RA (RA-BEAM [25], RA-BUILD [26]);
RA-BEAM [25] included placebo (PBO) and ADA as
comparators, while RA-BUILD [26] included only PBO as
a comparator. The remaining RCT recruited patients with
RA who had experienced an inadequate response to TNFis
(TNFi-IR; RA-BEACON [27]). This RCT used PBO as a
comparator. Additionally, one long-term safety and toler-
ability study was included (RA-BEYOND [28]).
For the primary endpoint of an ACR20 response at
12 weeks follow-up, all three RCTs reported that BARI
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4 mg was statistically significantly superior to PBO
(pB 0.001). Furthermore, at 12 weeks, more patients
reached an ACR20 in the BARI 4 mg treatment arm than
the ADA treatment arm (p = 0.01). There was also an
advantage over PBO for BARI 4 mg at 24 weeks and
BARI 2 mg at 12 and 24 weeks follow-up. The most
common AEs for BARI were increases in low-density
lipoprotein cholesterol, upper respiratory tract infections,
and nausea; other adverse drug reactions included herpes
simplex, herpes zoster, acne, increased creatine phospho-
kinase, increased triglycerides, increased liver function
tests (aspartate transaminase, alanine transaminase), neu-
tropenia and thrombocytosis.
NMAs were performed to assess the relative efficacy of
BARI compared with the comparators in the cDMARD-IR
or TNFi-IR patients with moderate to severe RA. For the
base-case analysis at week 24 in the cDMARD-IR popu-
lation, BARI 4 mg in combination with cDMARDs was
associated with a statistically significant higher odds of an
ACR50 response compared with cDMARDs, ADA, PBO,
ETN and sulfasalazine (SSZ). No statistically significant
differences were found versus any other comparators for
the ACR50 outcome, with the exception of CTZ in com-
bination with cDMARDs, in which odds of ACR50
response were found to be significantly in favour of the
comparator. A similar pattern of results was observed for
BARI 2 mg.
For the base-case NMA at week 24 in the TNFi-IR
population, BARI 4 mg in combination with cDMARDs
demonstrated significantly higher ACR50 response rates
than the cDMARD comparator. No statistically significant
differences were found versus bDMARDs in combination
with cDMARDs, with the exception of the comparison of
BARI (both 4 and 2 mg in combination with cDMARDs)
with TCZ in combination with cDMARDs, and the com-
parison of BARI 2 mg in combination with cDMARDs
with RTX in combination with cDMARDs, in which sta-
tistically significant treatment effects in favour of the
comparators were observed.
A treatment effect in combination with cDMARDs was
assumed to be the same as a treatment effect in combina-
tion with MTX in the economic model.
3.1.1 Critique of the Clinical Evidence and Interpretation
The ERG found the searches for clinical-effectiveness
evidence reported in the CS to be adequate, and believed
that all published RCTs of BARI were included in the CS.
The eligibility criteria applied in the selection of evidence
for the clinical-effectiveness review were considered by the
ERG to be reasonable and consistent with the decision
problem outlined in the final NICE scope [3]. The quality
of the included RCTs was assessed using well-established
and recognised criteria.
The ERG stated that the results presented in the com-
pany’s NMAs should be treated with caution because
several problems were identified with the methods used. A
random-effects model was assumed for the study-specific
baseline treatment effects (pooling non-active and active
controls). Simultaneous models for baseline and treatment
effects were used, which means that the relative treatment
effects were also affected by the inappropriate pooling
among the baselines. Studies that reported EULAR
responses were synthesised along with EULAR response
outcomes converted from studies that only reported ACR
responses, which did not ensure that the relative rankings
of treatments are maintained. A random-effects model was
used for the cDMARD-IR population. In contrast, a fixed-
effect model was used for the TNFi-IR population since the
company stated that random-effects models were unsta-
ble and did not converge. The choice between the use of
fixed-effect and random-effects models should depend on
the objective of the analysis and the conduct of the inclu-
ded studies, rather than on model convergence.
3.2 Cost-Effectiveness Evidence Provided
by the Company
The manufacturer supplied a de novo discrete event sim-
ulation model constructed in Microsoft Excel (Microsoft
Corporation, Redmond, WA, USA). The model simulated
patients’ disease progressions through the sequences of
treatments being compared. For each treatment, patients
may achieve good, moderate or no EULAR response at
24 weeks. The EULAR response rates for each treatment
were based on the company’s NMAs. Patients who
achieved a moderate or good EULAR response were
assumed to have an improvement in Health Assessment
Questionnaire (HAQ) score and remained on treatment
until loss of efficacy (as assessed by a clinician), AE or
death. Patients who experienced no EULAR response dis-
continued treatment at 24 weeks and started the next
treatment in the sequence until they were receiving pal-
liative care alone. The HAQ score of a patient while
receiving bDMARDs or BARI treatment was assumed to
be constant following the initial response; in contrast, while
a patient was receiving cDMARDs or palliative care, HAQ
progression was assumed to be non-linear based on latent
HAQ trajectory classes [23]. Time to treatment discontin-
uation for responders was assumed independent of treat-
ment but was dependent on EULAR response category
(moderate or good) and was modelled using Weibull
curves fitted to British Society for Rheumatology Biologics
Register data. At treatment discontinuation, patients were
assumed to suffer a rebound in HAQ score equal to the
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improvement achieved on treatment initiation and were
started on the next treatment in the sequence. The mortality
rate was assumed to be affected by the HAQ score of a
patient at treatment initiation.
The model estimated the costs and quality-adjusted life-
years (QALYs) over patients’ remaining lifetimes. Euro-
Qol-5 Dimensions (EQ-5D) values were calculated based
on a mapping algorithm generated from HAQ scores and
patient characteristics [29]. Costs were considered from an
NHS perspective. The company’s analysis included costs
associated with drug acquisition, drug administration and
monitoring, and hospitalisation. Administration and moni-
toring costs were based on Technology Appraisal 375
(TA375) [16] and NHS Reference Costs 2014/15, hospi-
talisation costs and resource use estimates were based on
HAQ score bands as in previous NICE technology
appraisals, and drug costs were taken from the British
National Formulary [30]. An annual discount rate of 3.5%
was used for costs and outcomes. Serious AEs (SAEs) were
excluded from the base-case but were included in a sce-
nario analysis.
The analyses presented in the CS relate to four different
populations of RA patients: (1) cDMARD-IR patients with
moderate RA; (2) cDMARD-IR patients with severe RA;
(3) TNFi-IR patients with severe RA who were eligible for
RTX in combination with MTX; and (4) TNFi-IR patients
with severe RA for whom RTX in combination with MTX
was contraindicated or not tolerated. The definition of
severe RA was a DAS28[5.1, while moderate RA was
defined as a DAS28[3.2 andB 5.1. Baseline characteris-
tics of patients were based on the relevant clinical BARI
trials.
In the cDMARD-IR population with moderate RA, the
deterministic incremental cost-effectiveness ratio (ICER)
for BARI in combination with MTX compared with
intensive cDMARDs was estimated to be £37,420 per
QALY gained. In the cDMARD-IR population with severe
RA, BARI in combination with MTX dominated all com-
parators except for CTZ in combination with MTX; the
ICER of CTZ in combination with MTX compared with
BARI in combination with MTX was estimated to be
£18,400 per QALY gained.
In the TNFi-IR population with severe RA, when RTX
in combination with MTX was an option, BARI in com-
bination with MTX was dominated by RTX in combination
with MTX. In the TNFi-IR population with severe RA for
whom RTX in combination with MTX was contraindicated
or not tolerated, BARI in combination with MTX domi-
nated GOL in combination with MTX, and was less
effective and less expensive than the remaining compara-
tors. The ICERs for ETN biosimilars, CTZ and ADA, all in
combination with MTX, compared with BARI in combi-
nation with MTX were lower than £30,000 per QALY
gained. The ICERs for intravenous TCZ and subcutaneous
ABT, both in combination with MTX, compared with
BARI in combination with MTX were estimated to be
higher than £30,000 per QALY gained.
3.2.1 Critique of the Cost-Effectiveness Evidence
and Interpretation
The company’s model was based on the model developed
by the Assessment Group (AG) in NICE TA375 [16], with
some minor deviations. The ERG believed that the con-
ceptual model was appropriate but suffered from a series of
implementation errors and limitations.
The ERG noted that the company did not identify any
evidence on the effectiveness of ADA, CTZ, ETN and IFX
in combination with MTX in severe TNFi-IR patients. In
the absence of such data, the company used the same
efficacy estimates of these treatments in severe cDMARD-
IR patients instead, which is a favourable assumption for
these interventions; therefore, caution is advised when
interpreting these results. The company rounded modified
HAQ values to the nearest valid HAQ score rather than
allowing the valid HAQ score to be sampled probabilisti-
cally. The ERG noted that this approach might lead to
inaccurate estimations of HAQ scores as values might be
rounded up more often than rounded down or vice versa.
The company intended to implement the trajectory of
HAQ score while patients were receiving cDMARDs or
palliative care based on the latent class approach used by
the AG in TA375. However, the company assigned each
patient to a single class based on the probability of class
membership instead of using an average weighted by the
probability of class membership.
The company assumed that patients who achieve a
moderate or good EULAR response at 24 weeks experi-
ence a reduction in HAQ score instantaneously at treatment
initiation. The ERG believed that the company’s approach
is likely to lead to an overestimation of treatment benefits
in relation to savings in RA-related costs as the achieve-
ment of response would take at least a few weeks, and
potentially up to 24 weeks for some patients.
In order to calculate the QALYs and costs produced in
the time span between two events, the model used an area
under the curve (AUC) approach for the HAQ score and
then mapped this value to both an EQ-5D score and hos-
pitalisation costs; however, since the relationships between
HAQ score and EQ-5D, and between HAQ score and
hospitalisation costs, are not linear, this approach may lead
to inaccurate results.
The TCZ subcutaneous formulation was not included in
the list of comparators despite intravenous TCZ being
included. The company argued that it had excluded sub-
cutaneous TCZ because (1) the available evidence for
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subcutaneous TCZ was limited; (2) it provided a lower
efficacy estimate than for intravenous TCZ; and (3) the cost
difference between the two formulations was relatively
small. The ERG noted that the difference in costs might be
considerable, taking into account the administration costs
and the confidential Patient Access Scheme (PAS). Intra-
venous ABT was included in the NMA but was excluded
from the analyses. In response to a clarification request by
the ERG, the company presented the results of intravenous
ABT only for the cDMARD-IR population with severe RA,
which led to similar results compared with subcutaneous
ABT.
The company used one of the algorithms proposed by
Herna´ndez Alava et al. [29] to map HAQ scores to EQ-5D.
The ERG noted that newer algorithms with a higher
accuracy have since been published, such as that reported
by Herna´ndez Alava et al. [31] and used in TA375.
3.3 Additional Work Undertaken by the ERG
The ERG’s critical appraisal identified a number of issues
relating to the company’s model and analysis. The ERG
believed that the NMA is subject to potential limitations;
some of the scenario analyses, as well as the PSA for the
severe TNFi-IR, RTX-ineligible population, lacked face
validity; the efficacy estimates for the cDMARD-IR pop-
ulation should only be used for the first-line of treatment;
rounding to the nearest HAQ score may have introduced
bias; the HAQ trajectory of a patient receiving cDMARDs
or palliative care should have been calculated as a
weighted average; assuming HAQ improvement upon
treatment initiation overestimated treatment benefit in
relation to savings in RA-related costs; averaging HAQ
across large time periods led to inaccuracies in the calcu-
lation of costs and QALYs; subcutaneous TCZ should have
been included in the list of comparators; newer mapping
algorithms from HAQ scores to EQ-5D should have been
used; BARI should have not been assumed to be provided
before intensive cDMARDs for moderate patients; mor-
tality rates differed between sequences; the distribution of
weight for interventions where the dosage is weight-based
should have been considered; and the dosage of IFX was
inaccurate.
The ERG re-analysed both the ACR and EULAR out-
comes at week 24 for both the cDMARD-IR and TNFi-IR
populations in the NMAs; however, due to the similarity in
efficacy between bDMARDs, the ERG undertook few
exploratory analyses, except amending two programming
errors that affected the company’s PSA results.
3.3.1 Additional Network Meta-Analyses
In the ERG’s NMAs, all cDMARDs were assumed to have
equivalent efficacy and were grouped together. The com-
pany provided data in the format for NMA for the
cDMARD-IR population EULAR outcomes. The ERG
amended the EULAR data used for van de Putte et al. [32]
so that the moderate EULAR responders did not include
good EULAR responders.
For EULAR outcomes in the TNFi-IR population, and
ACR outcome in the cDMARD-IR and TNFi-IR popula-
tion, the ERG computed the number of responses in each
category using the data provided in percentages reported in
the CS and in response to clarification request. The ERG’s
ACR NMA used the same included studies as those used in
the CS, while the ERG’s EULAR NMA only included
studies that reported EULAR outcomes, rather than intro-
ducing EULAR data converted from ACR data.
The model for the relative treatment effect used in the
ERG’s analyses was the same as in the NICE Decision
Support Unit Technical Support Document [33] and did not
assume a random-effects model for the baseline for each
study. The baseline and relative treatment-effect models
were run separately to make sure that the information in the
baseline model did not propagate to the relative treatment-
effect model.
A random-effects model was used for all ERG NMAs.
For the TNFi-IR population, since data were sparse, an
informative prior was assumed for the between-study
standard deviation, as suggested by Ren et al. [34]. This
was a lognormal distribution, with mean -2.56 and vari-
ance of 1.742, which was truncated so that the odds ratio in
one study would not beC 50 times than in another. It
represented the beliefs that heterogeneity being small was
15%, being moderate was 66%, and being high was 19%.
The NMAs conducted by the ERG had total residual
deviances, which indicated that the model used by the ERG
provided a better fit than those conducted by the company.
For EULAR outcomes in the cDMARD-IR population,
BARI 4 mg in combination with cDMARDs was associ-
ated with statistically significant beneficial treatment
effects relative to PBO and cDMARDs. No statistically
significant differences were found versus any other com-
parator, with the exception of TCZ in combination with
cDMARDs, which was associated with statistically bene-
ficial treatment effects relative to BARI 4 mg in combi-
nation with cDMARDs.
For ACR outcomes in the cDMARD-IR population,
BARI 4 mg in combination with cDMARDs was associ-
ated with statistically significant beneficial treatment
effects relative to PBO, cDMARDs and ADA monother-
apy. No statistically significant differences were found
versus any other comparator, with the exception of CTZ in
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combination with cDMARDs, which was associated with a
statistically significant beneficial treatment effect relative
to BARI 4 mg in combination with cDMARDs.
For EULAR outcomes in the TNFi-IR population, BARI
4 mg in combination with cDMARDs was associated with
statistically significant beneficial treatment effects relative
to cDMARDs. No statistically significant differences were
found versus RTX in combination with MTX, which was
the only other comparator in the network.
For ACR outcomes in the TNFi-IR population, BARI
4 mg in combination with cDMARDs was associated with
a statistically significant beneficial treatment effect relative
to cDMARDs. No statistically significant differences were
found versus any other comparator.
3.3.2 Exploratory Analyses for the Economic Model
The programming error that affected the PSA of the severe
cDMARD-IR population had a minimal impact on the
results; CTZ in combination with MTX had the greatest
probability of being most cost effective, at a cost per
QALY thresholds of £20,000 or more, followed by BARI
in combination with MTX. In contrast, the programming
error that affected the PSA of the severe TNFi-IR RTX-
ineligible population resulted in markedly higher costs and
QALYs gained for TCZ, ETN biosimilars, IFX biosimilars,
GOL and ADA, all in combination with MTX. As a result,
the affected comparators, with the exception of GOL,
shifted from the southwestern to the northeastern quadrant
in the cost-effectiveness plane compared with BARI in
combination with MTX, with ICERs ranging from £10,197
to £37,063, thus aligning with the results of the determin-
istic analysis for this population. CTZ in combination with
MTX had the greatest probability of being cost effective, at
a cost per QALY thresholds of £20,000 or more. The ERG
commented that the results in the TNFi-IR RTX-ineligible
population are confounded by the assumption for some
interventions that the EULAR responses obtained in the
cDMARD-IR population was applicable to the TNFi-IR
RTX-ineligible population.
3.4 Conclusions of the ERG Report
BARI in combination with MTX treatment was estimated
by the company to have an ICER of £37,420 per QALY
gained compared with intensive cDMARDs in the moder-
ate RA cDMARD-IR population, and shortcomings in the
analysis led the ERG to believe that the actual figure is
markedly higher. In the severe RA cDMARD-IR popula-
tion, BARI in combination with MTX dominated all its
comparators, except for CTZ in combination with MTX;
the ICER of CTZ in combination with MTX compared
with BARI in combination with MTX was estimated to be
£18,400 per QALY gained. In the severe RA TNFi-IR
population, when RTX in combination with MTX was an
option, BARI in combination with MTX was dominated by
RTX in combination with MTX. In patients with severe RA
who have had inadequate response to a TNFi and for whom
RTX in combination with MTX is contraindicated or not
tolerated, BARI in combination with MTX dominated
GOL in combination with MTX and was less effective and
less expensive than the rest of its comparators. The ICERs
for ETN biosimilars and ADA, all in combination with
MTX, compared with BARI in combination with MTX,
were estimated to be lower than £30,000 per QALY
gained, while the ICERs for intravenous TCZ and subcu-
taneous ABT, both in combination with MTX, compared
with BARI in combination with MTX, were estimated to be
higher than £30,000 per QALY gained; however, the
confidential PASs for ABT and TCZ were not included in
these analyses and the results in the TNFi-IR RTX-ineli-
gible population are confounded by the assumption for
some interventions that the EULAR responses obtained in
a cDMARD-IR population was applicable to the TNFi-IR
RTX-ineligible population.
4 Key Methodological Issues
The company used a random-effects model for the study-
specific baseline treatment effects that inappropriately
pooled the non-active and active controls. In addition,
studies that reported EULAR responses were synthesised
along with converted EULAR response outcomes from
studies that only reported ACR responses. A random-ef-
fects model was used for the cDMARD-IR population. In
contrast, a fixed-effect model was used for the TNFi-IR
population, given the justification that random-effects
models were unstable and did not converge.
With the agreement of NICE, errors that were identified
were not amended if they did not change the conclusions.
This was the case where the efficacy of the bDMARDs was
similar. As such, this was an informal pilot for NICE’s fast-
track appraisals.
5 National Institute for Health and Care
Excellence Guidance
In June 2017, on the basis of the evidence available (in-
cluding verbal testimony of invited clinical experts and
patient representatives), the AC produced guidance that
BARI in combination with MTX was recommended as an
option following an inadequate response to intensive
therapy with cDMARDs for treating severe RA. It was also
recommended as an option, following an inadequate
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response to other DMARDs, including at least one
bDMARD, for treating severe RA if patients could not
receive RTX in combination with MTX. The AC also
produced guidance that BARI monotherapy was recom-
mended if MTX was contraindicated or not tolerated, under
the same criteria as for combination treatment. All rec-
ommendations were conditional on the company providing
BARI with the agreed PAS.
5.1 Consideration of Clinical and Cost-Effectiveness
Issues Included in the Final Appraisal
Determination
This section summarises the key issues considered by the
AC. The full list of the issues considered by the AC can be
found in the FAD [35].
5.1.1 Current Clinical Management
In England, the AC considered the current clinical man-
agement for people with severe RA that has not responded
to intensive treatment with combinations of conventional
DMARDs, and noted that the NICE guidance recommends
the following bDMARDs: ADA, ETN, IFX, CTZ, ABT,
TCZ and GOL (each with MTX). For people who meet
these criteria but cannot take MTX, the guidance recom-
mends that ADA, CTZ, ETN or TCZ may be used as
monotherapy. For people with severe RA who had had an
inadequate response to at least one TNFi, the guidance
recommends ADA, ETN, IFX, RTX and ABT (each with
MTX) as options. If RTX in combination with MTX is
contraindicated or withdrawn, the guidance recommends
ABT, ADA, ETN or IFX (each with MTX); however, if
MTX is contraindicated or withdrawn, the guidance rec-
ommends ADA, ETN, TCZ or CTZ. NICE also recom-
mends CTZ in combination with MTX following either a
TNFi or RTX.
5.1.2 Uncertainties in the Clinical Evidence
The AC considered the company’s clinical evidence and
accepted that the results showed that BARI was more
clinically effective than cDMARDs, and was as effective as
ADA for moderate to severe RA patients who had
responded inadequately to cDMARDs. Furthermore, the
AC considered that BARI is more clinically effective than
cDMARDs alone for moderate to severe RA patients who
had responded inadequately to bDMARDs, and that BARI
has a similar safety profile to cDMARDs and ADA.
The AC heard from the ERG that there were problems
with the methods used in the company’s NMAs. These
included the conversion of ACR data to EULAR data
before synthesis, the use of simultaneous models for
baseline and treatment effects, the use of a random-effects
model for one population and a fixed-effects model for the
other, and poor model fit. In addition, the company had
pooled the control data inappropriately. The ERG corrected
the errors in the company’s NMAs. Having reviewed both
analyses, the AC concluded that the results of the corrected
NMAs and the company’s NMAs were broadly
comparable.
5.1.3 Uncertainties in the Economic Modelling
The AC had some concerns with how costs were calcu-
lated. The company’s model included costs associated with
drug acquisition, drug administration and monitoring, and
hospitalisation. The AC was aware that BARI and several
of the bDMARDs have PASs. It noted that the company
had incorporated the PAS prices for BARI, CTZ and GOL
into the model, but, as advised by NICE, not the confi-
dential PAS for ABT and TCZ. The company had also
calculated the average cost of drug doses using the average
weight, rather than the distribution of the weight of the
modelled patient population. The AC was also aware that
the company overestimated the number of doses, and
therefore the costs, of IFX.
The AC had concerns that the company was likely to
have overestimated the efficacy of ADA, CTZ, ETN and
IFX in combination with MTX in severe TNFi-IR patients.
The company assumed the same efficacy estimates of these
treatments as those in severe cDMARD-IR patients
because of the lack of evidence for these treatments. Where
data on both were available, the EULAR responses for all
treatments were higher in these patients than in those with
an inadequate response to bDMARDs.
6 Conclusions
The evidence suggests that BARI in combination with
MTX or as monotherapy has a comparable efficacy for
treating moderate to severe RA as that of other bDMARDs
already recommended by NICE. The economic analyses
conducted by the company and the ERG estimated ICERs
within the range usually considered by NICE as a cost-
effective use of NHS resources for BARI in combination
with MTX or as monotherapy versus some or all of its
comparators in the considered populations. The exception
was for TNFi-IR RTX-eligible patients and patients with
moderate RA. Consequently, NICE recommended BARI in
combination with MTX as an option for patients with
severe RA who can tolerate MTX if (1) they have
cDMARD-IR; (2) they have TNFi-IR, and RTX in com-
bination with MTX is not an option; or (3) they have TNFi-
IR and have already been treated with RTX in combination
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with MTX. NICE recommended BARI monotherapy for
cDMARD-IR and TNFi-IR patients with severe RA who
cannot tolerate MTX.
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